{"name":"Allakos Inc.","slug":"allakos-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"AK001 low dose","genericName":"AK001 low dose","slug":"ak001-low-dose","indication":"Other","status":"phase_2"},{"name":"AK001","genericName":"AK001","slug":"ak001","indication":"Other","status":"phase_1"},{"name":"AK006 IV","genericName":"AK006 IV","slug":"ak006-iv","indication":"Other","status":"phase_1"},{"name":"AK006-SC","genericName":"AK006-SC","slug":"ak006-sc","indication":"Other","status":"phase_1"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AK001 high dose","genericName":"AK001 high dose","slug":"ak001-high-dose","indication":"Eosinophilic gastroenteritis","status":"phase_2"}]}],"pipeline":[{"name":"AK001 high dose","genericName":"AK001 high dose","slug":"ak001-high-dose","phase":"phase_2","mechanism":"AK001 is a bispecific antibody that simultaneously engages Siglec-8 on eosinophils and mast cells while cross-linking them to trigger cell death and reduce type 2 inflammation.","indications":["Eosinophilic gastroenteritis","Eosinophilic colitis","Mast cell activation disorder"],"catalyst":""},{"name":"AK001 low dose","genericName":"AK001 low dose","slug":"ak001-low-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK001","genericName":"AK001","slug":"ak001","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK006 IV","genericName":"AK006 IV","slug":"ak006-iv","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK006-SC","genericName":"AK006-SC","slug":"ak006-sc","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiyAJBVV95cUxQVlZmM3hKUVRqX2duZFJna2RmWkdpUzVFZjNHZWplMnRHVVVqSHE5NG1vUldNaEx2ZjhoOW13cWtNWkg5NkJ6Y0ptVTMzeTc1eDBkWHUwTHpseVRVSDI3T0xXeFNhS1ktX2RlMmphZVJiNXQ5aF9zQnV0Y29kdHNJWUdQdnFDWVJmSXFSZ1p5ZXBRRmJTTHBfaE9vX0k4a0RadjBDZzNSeFRZSEpwYTNNc1lWRzFudlg1NWFKbEFQaW5ZY3YyYmFnRGg0RXJFMjVrR2prSmt0MU1PeVZxYW5uUTZLa2ZKT3QyQ3dRLUs2Vm5qRzFmeXVhT1JWejBmeERaQkFsQ21ub1FEM0FHeEotc2dEbk14U2d2ZWlOOGg4RTRVRS1pLVZDLU54YlR0TVkxTTdJZVpqWDNqSDlvY3UtY2s0R1A4eFlj?oc=5","date":"2026-04-07","type":"pipeline","source":"Barchart.com","summary":"Eosinophilic Esophagitis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Regeneron Pharma, Sanofi, Bristol-Myers Squibb, Ellodi Pharma, AstraZeneca, Allakos, EsoCap, Pfizer - Bar","headline":"Eosinophilic Esophagitis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Regeneron Pharma, Sanofi,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQa1EzVDFkU3FmY1VUajZ6ZXhnVnBNTjdURXNES3dsRVpYNDlRU1dweUg1Y3lIZ2ZueDhsTFo2anE2dHIyeHhFX1NDUU5pdUtBV3VFdl9vOUNCcU9NejhKZUJnY21jdy1ISFNrYWxYSlVWZl9kX1l1c2hVdUZfVlhaSUtWTDM4MHBzbTFiU3lBdFRDQkkz?oc=5","date":"2026-04-06","type":"trial","source":"openPR.com","summary":"Allergic Conjunctivitis Clinical Trials Landscape 2026: - openPR.com","headline":"Allergic Conjunctivitis Clinical Trials Landscape 2026:","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxQdEFnQktFM210eXdiZmRhVlE4Y3FUTndfak5Cell5OFgyR1Z1QWxsaks4TzU0NTBvZlJIc0o3enpwWTlTYXBFR3o4eFZNZUg2QUpEZGN5Z3ZsTFRqTmZOMVBSZVpoa1YxT3ZHbFlaVVJOZHBWZjFkSE1jSFpXSVVpYVl2U1VhSHRJS1daVHZkSHAtLW5nbW1aeWZIZk9CQUxLNnVlYVF6VVZNRVdtT3ZpVzhMVkI1ODFPLUpqLWpBU3dEVnpWSldBX1JaTmZaX1VTUFJEc0hubWtXZGVwWmw4UmlyLUpTbk5MYVhCRENwaVByRVhzZXhobF9wUGJNYzUtMGNzWEFqbkN3enFKdFplVjJnYzVPQVduMDAzZ1Jn?oc=5","date":"2025-12-08","type":"regulatory","source":"GlobeNewswire","summary":"Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma - GlobeNewswire","headline":"Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQSkV1TXBpaUp3UmtVUk8wdzlZQndORFZqck9TalJrSGZDbTY1enBQNW9xNVU5N3MweWF3Tk1WUk45cHJMRkVlaGdkREJnVnJVNEtRWEc0ay1HODVFUFpQWnBiWUwxbHo5ZHUzZ0lPSW9VX0k3Y09aQkJhTnJRaWhaN1RGbkZPdnlrY3BpZHlPUWdscjA2VTlGWTBjVFgwTExVTGxCTWJJRDNoaWc?oc=5","date":"2025-05-15","type":"deal","source":"Investing.com","summary":"Allakos completes merger with Concentra Biosciences - Investing.com","headline":"Allakos completes merger with Concentra Biosciences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQY0lWd1JMY3U1SzhTNWlLSGNMSUFGVDlMTlVpUDdXeXU3QV9HX1VvallwbWl1bUIxZmg2TXBhSkMwOTdWYldKeFpCVW9JcFc5WVZJUFY4Vk8yREk0UDZSbGlqZngwQ1lZSjBVNlI4ZGlncTdkYl8zdmdHa0c3T1p5TmhWYkNiVHE2eHowc3NnNEdobHNEdHc?oc=5","date":"2025-04-10","type":"pipeline","source":"Contract Pharma","summary":"Rivus Pharmaceuticals Expands Leadership Team - Contract Pharma","headline":"Rivus Pharmaceuticals Expands Leadership Team","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNMzhCVExFbkIxYWxFdUVJQUNXTkZfaE55emk4Zk5iZjdyTTZfandONDZSZ0FWYW5RV2YyX2luWVl5QVRpOFBGMUU5ZnkyT19FdUprNVhjZlpmNXFieWZET2JFckloUzdzMlcyNVVjWkNmSVZ2RXZlc0RhdTBFRkk2S2VaUnVTeUNXbF9ScE8wNVVkTThNNThiRG84aXp5T25HUGU2NFlJaF9QT3Z1QTAtMGdFbTZPWXl0Nmh5QkdjSWlVdw?oc=5","date":"2025-04-02","type":"deal","source":"Fierce Biotech","summary":"Concentra swoops in to buy struggling Allakos, softening the blow of other denied buyout attempts - Fierce Biotech","headline":"Concentra swoops in to buy struggling Allakos, softening the blow of other denied buyout attempts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPejRBV1ZWMGtxelhUTjljYVJweHRGbk9XTEhaRnIyUV9QU29POFotTUV5cFVoZ1RLMTBpcXRVYmlmNEVva0xEejdPcGtqSHNqOGtLbnJzckFNSk11QmVFR1BTMjVObmY3eTNnazViVVBHMks5UWpvWmdoYmluVXp2clA4OUZza3BCcUdBUFN4R2F0MnB2QjFSN0lmd3YxV1VFci1hYnhOQQ?oc=5","date":"2025-01-28","type":"trial","source":"Clinical Trials Arena","summary":"Allakos cuts 75% of workforce after chronic hives trial failure - Clinical Trials Arena","headline":"Allakos cuts 75% of workforce after chronic hives trial failure","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNa1FYM3RfUHBXNjZaNzFqd0NwWUVqcEJVZGhLdUlTaGg5bGY3Y2JQTEpYQjJpbkNzV29teUNBM1h1azZZRk1jLTlpWjlLNVROUzJYODE5Y25mTlVLcVhyTXJ4WEFvakoyT2t5bnNKYV9SSWVNdzFZaFdYN3BPRV9CR1NHei0yaUdU?oc=5","date":"2025-01-28","type":"trial","source":"The Pharma Letter","summary":"Allakos decimated as Phase I Trial of AK006 fails - The Pharma Letter","headline":"Allakos decimated as Phase I Trial of AK006 fails","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxNR280RVdVOEhBZmJUWi1CY0o2NnVQVHJxSWhiR05Va3VIb3d2aFB6RjdSRWM4a2U3clF5NVlfeWZOOUwwVEh5MGM2c0dnQlM5WUtJOUtERFVWOWNQM1ExUUhZS1ZtWWZVRWFjb2UyN05FZ0sydUlXV2U1OU9vRi03c1ZUNU1DdENJaThnUFMwcG9ncE44NGhZbkJOWm0wb0VXc19iRi1zS2Q3eWdQZm40aXlTX3U0ejFZcVJfSUVYcVVPckJnNExaRzlhT3h1ZHNqUmd5TDBUaWVnY1hfNFJ6YlVqcmtqUVdKaWc4?oc=5","date":"2024-07-02","type":"pipeline","source":"businesswire.com","summary":"Steven James, Accomplished CEO and Biotech Executive, Joins Board of Directors of Rondo Therapeutics - businesswire.com","headline":"Steven James, Accomplished CEO and Biotech Executive, Joins Board of Directors of Rondo Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQMmI4UXVzeXBvQUhfTEs2N0huYlFYclFlUVU3OHJyVEd1bk0xX3lLTXRfNDEwTm9BaVo2c29wU3J4ZlptakZpZ3JVMlpLSENiYWxUb0ZDX05RU2ZqMEcyNFk2NXR5VzNrNFRITGhDV3NmSmpoVmdJRWNkb3VhM2JXcmx3YzRyMlBfbkE?oc=5","date":"2024-04-09","type":"pipeline","source":"InvestorPlace","summary":"3 Biotech Stocks to Dump Before They Go to Zero - InvestorPlace","headline":"3 Biotech Stocks to Dump Before They Go to Zero","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPajh5TWxmNXhGTkZRN3gzNWVvUDBoRC13Mkd1V1gzLS00V3B4Zk5nNDlFQ2xRVWJrTjBXZUgzWnBoVXZCXzFsTEhMNGxBc0FxUXNib3o2dTdPLWF1WnJ5VDI0eGp2MDZlQll5THpqcE5tMFN4eHN2VnVHT3BIUTJ6clBqR3k5ZEd5eE1ocW1Cb0tzSVRMNTg0TVVKNFc?oc=5","date":"2024-01-16","type":"trial","source":"BioPharma Dive","summary":"Allakos to lay off half of staff, scrap drug after study setback - BioPharma Dive","headline":"Allakos to lay off half of staff, scrap drug after study setback","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1XLVNtYmhxNW1yUFByaWV3UkZUeG83bmJ3NVJDa3VzZ2hVdkVkRlE2N25HQmlDYVJGRVFyS0h4dGR3S1ljemxsR2RGYy1KVWpGQmNr?oc=5","date":"2022-09-12","type":"trial","source":"FirstWord Pharma","summary":"Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU) - FirstWord Pharma","headline":"Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (C","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_2":2,"phase_1":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}